• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

正常受控衰减参数值:韩国健康体检受试者和肝脏供体的前瞻性研究。

Normal controlled attenuation parameter values: a prospective study of healthy subjects undergoing health checkups and liver donors in Korea.

作者信息

Chon Young Eun, Jung Kyu Sik, Kim Kwang Joon, Joo Dong Jin, Kim Beom Kyung, Park Jun Yong, Kim Do Young, Ahn Sang Hoon, Han Kwang-Hyub, Kim Seung Up

机构信息

Department of Internal Medicine, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, Seoul, 120-752, Korea.

出版信息

Dig Dis Sci. 2015 Jan;60(1):234-42. doi: 10.1007/s10620-014-3293-1. Epub 2014 Aug 14.

DOI:10.1007/s10620-014-3293-1
PMID:25118979
Abstract

BACKGROUND/AIMS: The controlled attenuation parameter (CAP) is a noninvasive method of assessing hepatic steatosis. We defined the normal range of CAP values in healthy subjects and evaluated the associated factors.

METHODS

CAP values were measured in a cohort of healthy subjects who were screened as living liver transplantation donors and those who underwent health checkups. Subjects with current or a history of chronic liver disease, abnormalities on liver-related laboratory tests, or fatty liver on ultrasonography or biopsy were excluded.

RESULTS

The mean age of the 264 recruited subjects (131 males and 133 females; 76 potential liver donors and 188 subjects who had undergone health checkups) was 49.2 years. The mean CAP value was 224.8 ± 38.7 dB/m (range 100.0-308.0 dB/m), and the range of normal CAP values (5th-95th percentiles) was 156.0-287.8 dB/m. The mean CAP value was significantly higher in the health checkup than in the potential liver donor group (227.5 ± 42.0 vs. 218.2 ± 28.3 dB/m, P = 0.040). CAP values did not differ significantly according to gender or age in either group (all P > 0.05). In a multivariate linear regression analysis, body mass index (β = 0.271, P = 0.024) and triglyceride levels (β = 0.348, P = 0.008) were found to be independently associated with CAP values.

CONCLUSION

We determined the normal range of CAP values and found that body mass index and triglyceride levels were associated with the CAP values of healthy subjects.

摘要

背景/目的:受控衰减参数(CAP)是一种评估肝脂肪变性的非侵入性方法。我们定义了健康受试者CAP值的正常范围,并评估了相关因素。

方法

在一组被筛选为活体肝移植供体的健康受试者以及接受健康检查的受试者中测量CAP值。排除患有当前或既往慢性肝病、肝脏相关实验室检查异常、超声检查或活检显示脂肪肝的受试者。

结果

招募的264名受试者(131名男性和133名女性;76名潜在肝供体和188名接受健康检查的受试者)的平均年龄为49.2岁。平均CAP值为224.8±38.7 dB/m(范围100.0 - 308.0 dB/m),正常CAP值范围(第5 - 95百分位数)为156.0 - 287.8 dB/m。健康检查组的平均CAP值显著高于潜在肝供体组(227.5±42.0 vs. 218.2±28.3 dB/m,P = 0.040)。两组中CAP值在性别或年龄方面均无显著差异(所有P>0.05)。在多变量线性回归分析中,发现体重指数(β = 0.271,P = 0.024)和甘油三酯水平(β = 0.348,P = 0.008)与CAP值独立相关。

结论

我们确定了CAP值的正常范围,并发现体重指数和甘油三酯水平与健康受试者的CAP值相关。

相似文献

1
Normal controlled attenuation parameter values: a prospective study of healthy subjects undergoing health checkups and liver donors in Korea.正常受控衰减参数值:韩国健康体检受试者和肝脏供体的前瞻性研究。
Dig Dis Sci. 2015 Jan;60(1):234-42. doi: 10.1007/s10620-014-3293-1. Epub 2014 Aug 14.
2
Predicting Hepatic Steatosis in Living Liver Donors Via Controlled Attenuation Parameter.通过受控衰减参数预测活体肝供者的肝脂肪变性
Transplant Proc. 2018 Dec;50(10):3533-3538. doi: 10.1016/j.transproceed.2018.06.039. Epub 2018 Jun 30.
3
Usefulness of the controlled attenuation parameter for detecting liver steatosis in health checkup examinees.受控衰减参数在健康体检受检者中检测肝脂肪变性的效用。
Gut Liver. 2015 May 23;9(3):405-10. doi: 10.5009/gnl14202.
4
Clinical implications of controlled attenuation parameter in a health check-up cohort.健康检查队列中受控衰减参数的临床意义。
Liver Int. 2018 May;38(5):915-923. doi: 10.1111/liv.13558. Epub 2017 Sep 21.
5
Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.用于非酒精性脂肪性肝病中肝脂肪变性检测和定量的受控衰减参数
J Gastroenterol Hepatol. 2014;29(7):1470-6. doi: 10.1111/jgh.12557.
6
Clinical usefulness of controlled attenuation parameter to screen hepatic steatosis for potential donor of living donor liver transplant.控制衰减参数在活体肝移植潜在供体肝脂肪变性筛查中的临床应用价值
Eur J Gastroenterol Hepatol. 2017 Jul;29(7):805-810. doi: 10.1097/MEG.0000000000000876.
7
Validating controlled attenuation parameter in the assessment of hepatic steatosis in living liver donors.验证受控衰减参数在活体肝移植供体肝脂肪变性评估中的应用。
PLoS One. 2021 May 13;16(5):e0251487. doi: 10.1371/journal.pone.0251487. eCollection 2021.
8
Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography.应用瞬时弹性成像技术测量受控衰减参数无创检测无超声脂肪肝证据的患者肝脂肪变。
Eur J Gastroenterol Hepatol. 2013 Nov;25(11):1330-4. doi: 10.1097/MEG.0b013e3283623a16.
9
Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.受控衰减参数(CAP):基于瞬时弹性成像的肝脂肪变性非侵入性检测方法。
Liver Int. 2012 Jul;32(6):902-10. doi: 10.1111/j.1478-3231.2012.02781.x. Epub 2012 Mar 21.
10
Body mass index-based controlled attenuation parameter cut-offs for assessment of hepatic steatosis in non-alcoholic fatty liver disease.基于体重指数的控制衰减参数临界值在非酒精性脂肪性肝病肝脂肪变评估中的应用
Indian J Gastroenterol. 2020 Feb;39(1):32-41. doi: 10.1007/s12664-019-00991-2. Epub 2020 Mar 17.

引用本文的文献

1
Evaluation of Controlled Attenuation Parameter as a Tool for Assessment of Hepatic Steatosis in Living Liver Donors.评估受控衰减参数作为活体肝供者肝脂肪变性评估工具的研究
J Clin Exp Hepatol. 2025 Jul-Aug;15(4):102514. doi: 10.1016/j.jceh.2025.102514. Epub 2025 Feb 12.
2
Short-term outcome of bariatric surgery on nonalcoholic fatty liver disease: a Korean perspective.肥胖症手术对非酒精性脂肪性肝病的短期疗效:韩国视角
Ann Surg Treat Res. 2022 Jun;102(6):353-359. doi: 10.4174/astr.2022.102.6.353. Epub 2022 Jun 7.
3
Noninvasive Assessment of Hepatitis C Virus Infected Patients Using Vibration-Controlled Transient Elastography.

本文引用的文献

1
Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients.中国患者肝脏脂肪变性非侵入性评估的受控衰减参数
World J Gastroenterol. 2014 Apr 28;20(16):4702-11. doi: 10.3748/wjg.v20.i16.4702.
2
Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy.使用受控衰减参数和1H-磁共振波谱对非酒精性脂肪性肝病患者的肝脂肪变性进行无创评估。
PLoS One. 2014 Mar 17;9(3):e91987. doi: 10.1371/journal.pone.0091987. eCollection 2014.
3
Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy.
使用振动控制瞬时弹性成像技术对丙型肝炎病毒感染患者进行无创评估。
J Clin Med. 2021 Jun 10;10(12):2575. doi: 10.3390/jcm10122575.
4
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease.KASL临床实践指南:非酒精性脂肪性肝病的管理
Clin Mol Hepatol. 2021 Jul;27(3):363-401. doi: 10.3350/cmh.2021.0178. Epub 2021 Jun 22.
5
Validating controlled attenuation parameter in the assessment of hepatic steatosis in living liver donors.验证受控衰减参数在活体肝移植供体肝脂肪变性评估中的应用。
PLoS One. 2021 May 13;16(5):e0251487. doi: 10.1371/journal.pone.0251487. eCollection 2021.
6
Increased Hepatic Fat Content in Patients with Resistance to Thyroid Hormone Beta.抗甲状腺激素β受体患者肝内脂肪含量增加。
Thyroid. 2021 Jul;31(7):1127-1134. doi: 10.1089/thy.2020.0651. Epub 2021 Feb 19.
7
Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study.脂肪肝患者受控衰减参数与超声检查肝脂肪变程度的相关性:一项多中心回顾性队列研究。
Korean J Intern Med. 2020 Nov;35(6):1346-1353. doi: 10.3904/kjim.2018.309. Epub 2019 Nov 8.
8
Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病患者中使用瞬时弹性成像鉴别非酒精性脂肪性肝炎
PLoS One. 2016 Jun 10;11(6):e0157358. doi: 10.1371/journal.pone.0157358. eCollection 2016.
9
Comparison of Controlled Attenuation Parameter and Liver Biopsy to Assess Hepatic Steatosis in Pediatric Patients.比较受控衰减参数与肝脏活检以评估儿科患者的肝脂肪变性
J Pediatr. 2016 Jun;173:160-164.e1. doi: 10.1016/j.jpeds.2016.03.021. Epub 2016 Mar 30.
10
Noninvasive Prediction of Erosive Esophagitis Using a Controlled Attenuation Parameter (CAP)-Based Risk Estimation Model.使用基于受控衰减参数(CAP)的风险估计模型对糜烂性食管炎进行无创预测。
Dig Dis Sci. 2016 Feb;61(2):507-16. doi: 10.1007/s10620-015-3902-7. Epub 2015 Oct 6.
使用受控衰减参数检测肝脂肪变性:与肝活检的对比研究。
Scand J Gastroenterol. 2014 May;49(5):611-6. doi: 10.3109/00365521.2014.881548. Epub 2014 Mar 11.
4
Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.用于非酒精性脂肪性肝病中肝脂肪变性检测和定量的受控衰减参数
J Gastroenterol Hepatol. 2014;29(7):1470-6. doi: 10.1111/jgh.12557.
5
How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound.在普通人群中,控制衰减参数和脂肪肝指数评估肝脂肪变性的效果如何:与超声的相关性
Liver Int. 2014 Jul;34(6):e111-7. doi: 10.1111/liv.12305. Epub 2013 Sep 4.
6
Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population.控制衰减参数(CAP)在慢性肝病患者肝脂肪变性检测中的应用:一项对韩国本地人群的前瞻性研究。
Liver Int. 2014 Jan;34(1):102-9. doi: 10.1111/liv.12282. Epub 2013 Sep 13.
7
Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography.应用瞬时弹性成像技术测量受控衰减参数无创检测无超声脂肪肝证据的患者肝脂肪变。
Eur J Gastroenterol Hepatol. 2013 Nov;25(11):1330-4. doi: 10.1097/MEG.0b013e3283623a16.
8
Association of glypican-4 with body fat distribution, insulin resistance, and nonalcoholic fatty liver disease.糖蛋白 4 与体脂分布、胰岛素抵抗和非酒精性脂肪性肝病的关系。
J Clin Endocrinol Metab. 2013 Jul;98(7):2897-901. doi: 10.1210/jc.2012-4297. Epub 2013 Apr 30.
9
Visceral fat predominance is associated with non-alcoholic fatty liver disease in Japanese women with metabolic syndrome.内脏脂肪优势与日本代谢综合征女性的非酒精性脂肪肝相关。
Hepatol Res. 2014 May;44(5):515-22. doi: 10.1111/hepr.12146. Epub 2013 May 22.
10
NAFLD in Asia--as common and important as in the West.亚洲的非酒精性脂肪性肝病——与西方一样普遍且重要。
Nat Rev Gastroenterol Hepatol. 2013 May;10(5):307-18. doi: 10.1038/nrgastro.2013.34. Epub 2013 Mar 5.